This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Idenix Pharmaceuticals, Inc. (IDIX)
Update on IDX184 Clinical Development Program Conference Call
August 16, 2012 08:30 am ET
Daniella Beckman - SVP & CFO
Ron Renaud - President & CEO
Doug Mayers - EVP & CMO
David Standring - EVP & CSO
Geoff Meacham - JPMorgan
Katherine Xu - William Blair
Yaron Werber - Citi
Howard Liang - Leerink Swann
Matt Roden - UBS
Daniel Brims - Brean Murray
Liisa Bayko - JMP
David Friedman - Morgan Stanley
Ying Huang - Barclays
Jim Birchenough - BMO Capital
Mark Schoenebaum - ISI Group
Yaron Werber - Citi
Good day ladies and gentlemen and welcome to the Idenix provides update on IDX184 clinical development conference call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will be given at that time. (Operator Instructions) As a reminder, today’s call is being recorded.
I would now like to turn the conference over to Ms. Daniella Beckman. Ma'am, you may begin.
Thank you. Good morning and welcome to Idenix Pharmaceuticals conference call to discuss the clinical development and status of our lead drug candidate, IDX184. My name is Daniella Beckman and I am the Chief Financial Officer at Idenix.
On this morning’s call is Ron Renaud, President and Chief Executive Officer; Doug Mayers, Chief Medical Officer, who has dialed in remotely and David Standring, Chief Scientific Officer.
Before we begin, I'll review our Safe Harbor statement. Today’s discussion contains statements that are forward-looking under the Private Securities Litigation Reform Act of 1995. Such statements are based on current expectations and assumptions that are subject to risks and uncertainties and involve a number of factors that could cause actual results to differ materially.